share_log

Vir Biotechnology Reiterates FY24 GAAP Combined R&D And SG&A Expense Range $650M-$680M

Benzinga ·  May 3 04:22
Vir Biotechnology Reiterates FY24 GAAP Combined R&D And SG&A Expense Range $650M-$680M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment